Takis Biotech
Zetesis X-eVax
Finding the Truth through rational Research
A Center of Excellence for next generation vaccines and gene therapies, hosting the entire research
chain in one place in Europe
What is Zetesis X-eVax?
Zetesis is an ancient Greek word that means: “finding the Truth through rational Research“
Zetesis X-eVax is an R&D and First Industrial Deployment project carried out by Takis with the objective to host the entire research chain on next generation vaccines in one place in Europe: from the idea to manufacturing of nucleic acid-based therapies.
X-eVax Platform
"X" stands for "Antigen X" and "e-Vax" for "vaccine delivery through electroporation". Our innovative platform enables rapid vaccine development using fully synthetic DNA technology.
Thermostable DNA
DNA is thermostable and does not need the cold chain, an essential feature for transport and storage in environments and countries with limited resources.
Proven Technology
COVID-eVax Phase 1 study achieved all objectives with promising results: the technology was immunogenic and particularly potent in the induction of T cell immune response.
IPCEI Recognition
Recognized as part of IPCEI (Important Project of Common European Interest) in Rome, representing a strategic investment in European health security.
A new, disruptive technology under development at Takis takes advantage of fully synthetic DNA, without the use of bacteria, with similar potency. The entire Research Chain is hosted in “Zetesis”, bringing together technologies to invent, develop, test in preclinical models and in human clinical trials unique Vaccines and Gene Therapies.
Our Vision
Changing Paradigm for Accelerated Regulatory Pathway in Europe
Objectives
Zetesis
A Center of excellence for reverse vaccinology and gene therapies: from the idea to proof of concept to First Industrial Deployment
FIDIA
(Fabbrica Italiana del DNA per l'Immunoterapia Applicata) To allow a scalable production of small scale, personalized and large-scale vaccines in short time frames, everywhere.
Pipeline
Application of Takis' X-eVax technology to develop products against: COVID-19, Cancer, Malaria and other infectious diseases.
Translational Disease Platform
Make available innovative and predictive preclinical models and know how thereof for the development of new therapies within IPCEI Med4Cure network.